Yeung, David

The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia

Fox, L. C., Cummins, K. D., Costello, B., Yeung, D., Cleary, R., Forsyth, C., Tatarczuch, M., Burbury, K., Motorna, O., Shortt, J., et al. (2017) · Blood Advances

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 43

De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways

Magistroni, V., Mauri, M., D’Aliberti, D., Mezzatesta, C., Crespiatico, I., Nava, M., Fontana, D., Sharma, N., Parker, W., Schreiber, A., et al. (2019) · Haematologica

Chronic Myeloid Leukemia TreatmentsAcute Myeloid Leukemia Research

Cited by 29

Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study

Yeung, D. T., Shanmuganathan, N., Reynolds, J., Branford, S., Walia, M., Yong, A. S. M., Shortt, J., Chee, L., Viiala, N., Cunningham, I., et al. (2024) · Blood

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 27

Evidence-based risk stratification of myeloid neoplasms harboring TP53 mutations

Shah, M. V., Hung, K., Baranwal, A., Kutyna, M. M., Al-Kali, A., Toop, C., Greipp, P., Brown, A., Shah, S., Khanna, S., et al. (2025) · Blood Advances

Acute Myeloid Leukemia ResearchChronic Myeloid Leukemia Treatments

Cited by 23

Strong Association between Cancer Gene Variants at Diagnosis, Especially ASXL1, and Emergence of Kinase Domain Mutation-Driven Resistance in CML Patients Despite Frontline Treatment with More Potent BCR::ABL1 Inhibitors

Shanmuganathan, N., Wadham, C., Yeung, D. T., Shahrin, N. H., Fernandes, A., Maqsood, M., Kok, C. H., Saunders, V. A., Pagani, I. S., Kenyon, R., et al. (2024) · Blood

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 12